Current Report Filing (8-k)
August 11 2022 - 05:26PM
Edgar (US Regulatory)
0001130598 false 0001130598 2022-08-11
2022-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
August 11, 2022
Onconova Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
Delaware |
|
001-36020 |
|
22-3627252 |
(State or Other
Jurisdiction
of Incorporation or Organization) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
12 Penns Trail
Newtown,
PA
18940 |
(267)
759-3680 |
(Address, Including Zip Code, and
Telephone Number, Including Area Code, of Registrant’s Principal
Executive Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par
value $.01 per share |
|
ONTX |
|
The Nasdaq Stock
Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2022, Onconova Therapeutics, Inc. (the “Company”)
issued a press release announcing its financial results for the
quarter ended June 30, 2022, a copy of which is attached hereto as
Exhibit 99.1 and incorporated herein by reference. The information
contained in this Form 8-K (including the exhibit hereto) shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
Dated: August
11, 2022 |
Onconova Therapeutics, Inc. |
|
|
|
By: |
/s/ MARK GUERIN |
|
|
Name: Mark
Guerin |
|
|
Title: Chief
Operating Officer & Chief Financial Officer |
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Jan 2023 to Feb 2023
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Feb 2022 to Feb 2023